bioRxiv Science⌕ Search

bioRxiv · 10.1101/299214

Human Papillomavirus Type 16 L1/L2 VLP Experimental Internalisation by Human Peripheral Blood Leukocytes

Abstract

Human papillomavirus (HPV) accounts for hundreds of thousands of new cases of cervical cancer yearly, and half of these women die of this neoplasia. This study investigates the possibility of HPV16 L1/L2VLP to be internalized by human peripheral blood leukocytes in ex vivo assays. We have developed a leukocyte separation method from heparinized blood samples aiming cellular integrity and viability. We have expressed humanized L1 and L2 viral capsid proteins in HEK293T epithelial human cells, transiently transfecting them with vectors encoding humanized HPV16 L1 and L2 genes. Recombinant L1/L2 capsid proteins and structured virus-like particles interacted with human peripheral blood mononuclear cells, lymphocytes and monocytes, and were internalized through a pathway involving CD71 transferrin receptors. This was observed, at a percentile of about 54% T- CD4, 47% T-CD8, 48% B-CD20, and 23% for monocytes-CD14. The group of polymorph nuclear cells: neutrophils-eosinophils-basophils group did not internalize any VLPs. Blockage assays with biochemical inhibitors of distinct pathways, like chlorpromazine, rCTB, filipin, nystatin, liquemin, and sodium azide also evidentiated the occurrence of virus-like particles indiscriminate entrance via membrane receptor on mononuclear cells. This study shows that HPV16 L1/L2 VLPs can interact with the plasma membrane surface and successfully enter lymphocytes without requiring a specific receptor. Legend of the Graphical AbstractGraphical abstract showing ex vivo and in vitro internalization between VLPs and host cells. After leukocytes separation from human whole blood, it was performed the identification of human peripheral blood leukocytes in ex vivo interactions with VLPs. The graph shows that of the cells that interacted with VLPs, 52% corresponded to lymphocytes T-CD4, 47% lymphocytes T-CD8, 48% lymphocytes B-CD20, and only 23% of the monocytes CD14 interacted with these particles. However, monocytes apparently internalized larger amounts of particles when compared to lymphocytes. It is probable that in some T lymphocytes the amount of internalized particles has been imperceptible to the confocal microscope, since the VLPs produced in this research are around 50 nm in diameter. These results lead to two important implications. First, the interaction of VLPs with lymphocytes may result in the activation of these cells and, consequently, increase the population of these circulating cells, this being crucial in the induction of specific immune response. In the second implication, these lymphocytes would internalize small amounts of virus, insufficient to activate the immune system. Here it is important to note that lymphocytes are cells capable of dividing and it is estimated that the half-life of these inactive cells in humans is of some years. In addition, as it is known, inactive lymphocytes continually re-circulate through the bloodstream and lymphatic vessels. The percentage of cells that interacted with the HPV16 L1/L2 VLPs was calculated by the number of cells recognized by the anti-CD antibodies, which internalized these particles. The result corresponds to the analysis in duplicates, being representative of at least four tests. All images are original and cells were processed by Cianciarullo AM et al., at the Butantan Institute, Sao Paulo - SP, Brazil. Electron micrographs of human leukocytes, HEK293T and HPV16 L1/L2 VLPs were obtained in a Zeiss EM109 transmission electron microscope. The blue color of the VLPs and colored leukocytes were virtually attributed. Leukocyte and HEK293T present filamentous actin (red) and HPV16 L1/L2 VLPs (green), by fluorescence in a Confocal Zeiss LSM 510 Meta Microscope O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=195 SRC="FIGDIR/small/299214v2_ufig1.gif" ALT="Figure 1"> View larger version (68K): org.highwire.dtl.DTLVardef@1ee89b8org.highwire.dtl.DTLVardef@193d0a6org.highwire.dtl.DTLVardef@1674526org.highwire.dtl.DTLVardef@ecd80d_HPS_FORMAT_FIGEXP M_FIG C_FIG

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Cianciarullo, A. M., Szulczewski, V., Kavati, E. A., Hosoda, T. M., Leao, E., Borelli, P., Boccardo, E., Mueller, M., Karanam, B., Becak, W.. 2018-04-11. Human Papillomavirus Type 16 L1/L2 VLP Experimental Internalisation by Human Peripheral Blood Leukocytes. https://doi.org/10.1101/299214

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Polycomb Marked Promoter Methylation Gains in Aging and Cancer are Independent of Replication

DNA methylation alterations are hallmark features of aging and cancer, occurring early during tumor initiation. Yet how these changes evolve during early tumorigenesis, and whether oncogenic signaling actively drives them, remains poorly understood due to limitations in resolving this at the longitudinal and clonal level. Here we developed a genome-wide DNA methylation profiling method for low DNA amounts and applied it to single stem cell-derived clones from a BRAFV600E -inducible mouse colon organoid model, tracking nucleotide-level methylation heterogeneity over time. BRAFV600E induction produced stepwise methylation divergence consistent with progressive clonal takeover, in contrast to gradual epigenetic drift in uninduced controls. Strikingly, while the specific CpG sites altered differed between BRAFV600E and control lineages, they converged on the same genomic elements. Particularly, Polycomb-marked promoter CpG-island methylation gains were not induced or accelerated by BRAFV600E, challenging models in which oncogenic signaling or cell proliferation actively instructs de novo methylation of Polycomb-targeted promoters. Instead, these gains tracked with "biological aging" independent of replication, which was validated across independent aging, cancer, and cell-line datasets. BRAFV600E -induced clones additionally showed progressive loss of intestinal lineage-specification transcription factor programs, consistent with selection for cells adapted to oncogenic stress. Together, these findings show that epigenetic trajectories during early tumor development, are rooted in baseline, age-dependent drivers of epigenetic alterations, and that oncogenic signaling acts primarily by selecting and expanding clones bearing pre-existing, age-associated epigenetic drift rather than instructing new methylation. Our findings have implications for how promoter methylation is interpreted as a cancer biomarker and for identifying upstream aging-associated processes as targets for early intervention.

cancer biology↗

ORTHOTOPIC TUMOUR INDUCTION PROTOCOL SHAPES TUMOUR MICROENVIRONMENT

Robust preclinical cancer models are essential for studying tumour progression and evaluating therapeutic strategies. Orthotopic implantation of tumour cells into the mammary gland is widely used to model triple-negative breast cancer (TNBC), yet substantial variation exists in the number of cells used to initiate tumours, often without explicit consideration of how this parameter shapes tumour biology. Here, we systematically assess how tumour cell number at implantation influences the tumour microenvironment using the 4T1 orthotopic TNBC model. Mammary tumours initiated with different cell numbers exhibited comparable early growth kinetics and gross size, yet diverged markedly in cellular density, hypoxia, necrosis, proliferation, vascular integrity, and immune cell infiltration. High-density tumours displayed increased HIF-1 staining and necrosis, alongside differences in vascular-associated markers and increased macrophage recruitment. Conversely, low-density tumours remained highly proliferative, less necrotic and exhibited higher PDGFR{beta} staining. Importantly, tumour cells disseminated systemically within days of implantation across all conditions, although differences in colony recovery and ex vivo expansion were not statistically significant. Together, these findings demonstrate that tumour initiating protocols are powerful determinants of tumour state, with potential implications for dissemination frequency and tumour cell fate at distant sites. Rather than representing a source of experimental variability alone, this understanding provides an opportunity to intentionally tailor orthotopic models to investigate specific stages of disease progression and therapeutic response, thereby enhancing cross-study reproducibility and translational relevance.

cancer biology↗

Single-cell characterization of 3D CLL spheroid model that recapitulates lymph node microenvironment-driven phenotypes and in vivo drug responses to ibrutinib

Lymph node (LN) microenvironmental signals promote chronic lymphocytic leukemia (CLL) cell survival, proliferation, and treatment resistance. We previously developed a 3D culture model that recapitulates key features of this protective LN niche. Using single-cell RNA sequencing of ex vivo paired peripheral blood and LN samples, together with matched patient-derived CLL spheroids, we investigated how microenvironmental cues shape CLL phenotypes and their response to ibrutinib. A total of 3 functional CLL states (resting, activated, proliferating) were identified, with expanded populations of activated and proliferating subsets in 3D cultures. After 5 days of in vitro ibrutinib treatment, CLL cells shifted toward a resting phenotype, reflecting published responses in patients at 6 months. Activated CLL cells showed relative resistance to ibrutinib, associated with TLR9-MALT1-MYC pathway activation. The 3D model recapitulated tissue-specific T cell phenotypes observed in patients, and computational analyses predicted several T-to-CLL cell-mediated interactions supporting the LN niche. Collectively, these data reveal distinct ibrutinib responses among CLL subsets and establish the 3D model as a physiologically relevant platform.

cancer biology↗